The worldwide need for an effective herpes simplex virus (HSV) vaccine remains a priority because it is a common infection that causes physical and economic disadvantages.
A new study published by Nature on November 6, 2020, reported the recent ‘failure of the subunit gD2 vaccine in a clinical trial demonstrated that new approaches to HSV vaccines are needed, especially those that present multiple HSV antigens.’
Read More
